Insulin Dose Adjustment in Patients with Declining Renal Function

Pathophysiology and Risk Factors

Approximately one-third of insulin degradation occurs in the kidneys, and impaired kidney function prolongs insulin half-life, according to the American Journal of Kidney Diseases 1, 2
Patients with elevated creatinine levels experience a 5-fold increase in severe hypoglycemia frequency when receiving insulin, as reported by the American Journal of Kidney Diseases 1, 3
Reduced kidney mass impairs renal gluconeogenesis, further compromising the body's defense against hypoglycemia, as noted by the American Journal of Kidney Diseases 1, 3

The American Journal of Kidney Diseases recommends decreasing Lantus dose by 25-50% initially, as insulin clearance is significantly impaired at GFR <60 1, 2
Intensive glucose monitoring (at least 4 times daily) should be implemented to detect hypoglycemia early, as suggested by the American Journal of Kidney Diseases 1, 3

The American Journal of Kidney Diseases advises avoiding metformin if creatinine ≥1.4 mg/dL in women or ≥1.5 mg/dL in men due to lactic acidosis risk 1, 3
Glipizide is preferred over other sulfonylureas if using this class, as it lacks active metabolites, according to the American Journal of Kidney Diseases 1, 2

The American Journal of Kidney Diseases warns that never ignoring rising creatinine in insulin-treated patients can result in life-threatening hypoglycemia 1, 2
Relying solely on HbA1c at this GFR level is not recommended, as reduced red blood cell lifespan and other factors may cause falsely low values, as noted by the American Journal of Kidney Diseases 3